MX2016000721A - Direccionamiento de antagonistas de citocinas. - Google Patents

Direccionamiento de antagonistas de citocinas.

Info

Publication number
MX2016000721A
MX2016000721A MX2016000721A MX2016000721A MX2016000721A MX 2016000721 A MX2016000721 A MX 2016000721A MX 2016000721 A MX2016000721 A MX 2016000721A MX 2016000721 A MX2016000721 A MX 2016000721A MX 2016000721 A MX2016000721 A MX 2016000721A
Authority
MX
Mexico
Prior art keywords
targeting
cytokine
cytokine antagonists
fusion protein
receptor
Prior art date
Application number
MX2016000721A
Other languages
English (en)
Inventor
Tavernier Jan
Zabeau Lennart
Uzé Gilles
Paul Franciane
Bordat Yann
Garcin Geneviève
Original Assignee
Vib Vzw
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vib Vzw filed Critical Vib Vzw
Publication of MX2016000721A publication Critical patent/MX2016000721A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/56—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/642—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a cytokine, e.g. IL2, chemokine, growth factors or interferons being the inactive part of the conjugate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2869—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against hormone receptors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor

Abstract

La presente invención se refiere a una proteína de fusión, que comprende un antagonista de citocina y un resto de direccionamiento, preferentemente, a un anticuerpo o una molécula similar a anticuerpo. En una modalidad preferida, el antagonista de citocina es una citocina modificada que se une al receptor, pero no induce la señalización del receptor. La invención además se refiere a una proteína de fusión de acuerdo con la invención para utilizar en el tratamiento del cáncer o trastornos relacionados con la inflamación o el sistema inmunitario.
MX2016000721A 2013-07-19 2014-07-01 Direccionamiento de antagonistas de citocinas. MX2016000721A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP13306045 2013-07-19
PCT/EP2014/063976 WO2015007520A1 (en) 2013-07-19 2014-07-01 Targeting of cytokine antagonists

Publications (1)

Publication Number Publication Date
MX2016000721A true MX2016000721A (es) 2016-09-07

Family

ID=48874233

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016000721A MX2016000721A (es) 2013-07-19 2014-07-01 Direccionamiento de antagonistas de citocinas.

Country Status (11)

Country Link
US (5) US9732135B2 (es)
EP (1) EP3022230B1 (es)
JP (1) JP6475712B2 (es)
KR (1) KR102305608B1 (es)
CN (1) CN105658669A (es)
AU (1) AU2014292355B2 (es)
CA (1) CA2918119C (es)
IL (1) IL243459B (es)
MX (1) MX2016000721A (es)
SG (2) SG10202010429YA (es)
WO (1) WO2015007520A1 (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6416628B2 (ja) * 2012-01-20 2018-10-31 ブイアイビー ブイゼットダブリュＶｉｂ Ｖｚｗ 標的変異体αヘリックスバンドルサイトカイン
SG10202010429YA (en) * 2013-07-19 2020-11-27 Vib Vzw Targeting of cytokine antagonists
EP3371311B1 (en) 2015-11-06 2021-07-21 Orionis Biosciences BV Bi-functional chimeric proteins and uses thereof
EP3998281A1 (en) 2016-02-05 2022-05-18 Orionis Biosciences BV Cd8 binding agents
US11661455B2 (en) 2016-02-05 2023-05-30 Orionis Biosciences BV Chimeric protein comprising an interferon alpha 2mutant and a PD-L1 binding moiety
EP3426278B1 (en) * 2016-03-07 2024-01-03 Vib Vzw Cd20 binding single domain antibodies
EP3426687A1 (en) * 2016-03-07 2019-01-16 VIB vzw Cd20 binding agents and uses thereof
JP7105200B2 (ja) 2016-05-13 2022-07-22 オリオニス バイオサイエンシズ ビーブイ 標的突然変異体インターフェロン－ベータおよびその使用
WO2017194782A2 (en) 2016-05-13 2017-11-16 Orionis Biosciences Nv Therapeutic targeting of non-cellular structures
ES2917000T3 (es) 2016-10-24 2022-07-06 Orionis Biosciences BV Interferón-gamma mutante diana y usos del mismo
US10906985B2 (en) 2017-02-06 2021-02-02 Orionis Biosciences, Inc. Targeted engineered interferon and uses thereof
KR102642385B1 (ko) 2017-02-06 2024-03-04 오리오니스 바이오사이언시스 엔브이 표적화된 키메라 단백질 및 이의 용도
US11246911B2 (en) 2017-02-07 2022-02-15 Vib Vzw Immune-cell targeted bispecific chimeric proteins and uses thereof
WO2019032661A1 (en) 2017-08-09 2019-02-14 Orionis Biosciences Inc. CD8 LIAISON AGENTS
WO2019032663A1 (en) 2017-08-09 2019-02-14 Orionis Biosciences Inc. PD-1 AND PD-L1 BINDING AGENTS
US11896643B2 (en) 2018-02-05 2024-02-13 Orionis Biosciences, Inc. Fibroblast binding agents and use thereof
CN111499718B (zh) * 2019-01-30 2022-06-14 复旦大学 人α干扰素受体结合相关位点突变体及其用途
CA3133643A1 (en) 2019-03-28 2020-10-01 Orionis Biosciences, Inc. Therapeutic interferon alpha 1 proteins
AU2020312735A1 (en) 2019-07-18 2021-12-16 Enyo Pharma Method for decreasing adverse-effects of interferon
WO2022200525A1 (en) 2021-03-26 2022-09-29 Innate Pharma Multispecific proteins comprising an nkp46-binding site, a cancer antgienge binding site fused to a cytokine for nk cell engaging
WO2022258691A1 (en) 2021-06-09 2022-12-15 Innate Pharma Multispecific proteins binding to nkg2d, a cytokine receptor, a tumour antigen and cd16a
WO2022258678A1 (en) 2021-06-09 2022-12-15 Innate Pharma Multispecific proteins binding to nkp30, a cytokine receptor, a tumour antigen and cd16a
EP4352098A1 (en) 2021-06-09 2024-04-17 Innate Pharma Multispecific proteins binding to nkp46, a cytokine receptor, a tumour antigen and cd16a
US20240067691A1 (en) 2022-08-18 2024-02-29 Regeneron Pharmaceuticals, Inc. Interferon receptor agonists and uses thereof
WO2024040247A1 (en) 2022-08-18 2024-02-22 Regeneron Pharmaceuticals, Inc. Interferon proproteins and uses thereof

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE103932T1 (de) 1989-08-22 1994-04-15 Immunex Corp Fusionsprotein bestehend aus gm-csf und il-3.
US6277969B1 (en) 1991-03-18 2001-08-21 New York University Anti-TNF antibodies and peptides of human tumor necrosis factor
US5914254A (en) 1993-08-02 1999-06-22 Celtrix Pharmaceuticals, Inc. Expression of fusion polypeptides transported out of the cytoplasm without leader sequences
WO1997041232A1 (en) * 1996-04-26 1997-11-06 Beth Israel Deaconess Medical Center Antagonists of interleukin-15
MXPA02001417A (es) * 1999-08-09 2002-08-12 Lexigen Pharm Corp Complejos multiples de citosina-anticuerpo.
US20020193569A1 (en) * 2001-06-04 2002-12-19 Idec Pharmaceuticals Corporation Bispecific fusion protein and method of use for enhancing effector cell killing of target cells
EP1812038A1 (en) 2004-11-18 2007-08-01 VIB vzw Fibronectin iii domain as leptin receptor antagonists
WO2006115800A2 (en) 2005-04-15 2006-11-02 The Regents Of The University Of California Enhanced wound healing utilizing an anti-her2 antibody coupled to a tnf alpha
ES2435846T3 (es) * 2005-06-29 2013-12-23 Yeda Research And Development Co. Ltd. Mutantes de Interferón alfa 2 (IFN alfa 2) recombinante
CA2693326A1 (en) 2006-08-02 2008-02-07 Mcgill University Gm-csf and il-15 fusokines and methods for modulation of the immune response
US11535673B2 (en) 2007-04-05 2022-12-27 President and Fellows of Harvard CoHege Chimeric activators: quantitatively designed protein therapeutics and uses thereof
CA2690825C (en) * 2007-05-11 2019-02-12 Altor Bioscience Corporation Fusion molecules and il-15 variants
US20110038865A1 (en) 2007-06-26 2011-02-17 University Of Miami Antibody- endostatin fusion protein and its variants
MX2010003099A (es) 2007-09-21 2010-05-17 Univ California Interferon de objetivo demuestra actividades potentes apoptoticas y antitumorales.
WO2010030671A1 (en) * 2008-09-09 2010-03-18 University Of Medicine And Dentistry Of New Jersey Type i interferon antagonists
WO2010036918A2 (en) 2008-09-26 2010-04-01 University Of Massachusetts Intracellular dna receptor
AU2009326075B2 (en) 2008-12-08 2014-06-05 Complix Nv Single-chain antiparallel coiled coil proteins
JP5764127B2 (ja) 2009-08-17 2015-08-12 ロシュ グリクアート アーゲー 標的化イムノコンジュゲート
CN102497885A (zh) 2009-09-10 2012-06-13 赛托斯生物技术公司 白介素-1β突变蛋白偶联物在糖尿病治疗中的用途
EP2718457A4 (en) 2011-06-06 2014-12-24 Immungene Inc GENETICALLY MODIFIED FUSION MOLECULES LIGAND TNFSF-ANTIBODY ELEMENT
KR102037541B1 (ko) * 2011-10-28 2019-10-29 테바 파마슈티컬즈 오스트레일리아 피티와이 엘티디 폴리펩티드 구축물 및 이의 용도
JP6416628B2 (ja) * 2012-01-20 2018-10-31 ブイアイビー ブイゼットダブリュＶｉｂ Ｖｚｗ 標的変異体αヘリックスバンドルサイトカイン
PL2822575T3 (pl) 2012-03-03 2020-08-10 Immungene, Inc. Zmodyfikowane sposobami inżynierii cząsteczki fuzyjne przeciwciało-mutant interferonu
SG10202010429YA (en) * 2013-07-19 2020-11-27 Vib Vzw Targeting of cytokine antagonists

Also Published As

Publication number Publication date
AU2014292355A1 (en) 2016-02-04
US20160159875A1 (en) 2016-06-09
KR102305608B1 (ko) 2021-09-28
KR20160108292A (ko) 2016-09-19
US20180334489A1 (en) 2018-11-22
IL243459B (en) 2019-10-31
CN105658669A (zh) 2016-06-08
AU2014292355B2 (en) 2019-08-01
SG10202010429YA (en) 2020-11-27
US20210238247A1 (en) 2021-08-05
JP6475712B2 (ja) 2019-02-27
CA2918119A1 (en) 2015-01-22
US10947288B2 (en) 2021-03-16
WO2015007520A1 (en) 2015-01-22
SG11201600165WA (en) 2016-02-26
US10072059B2 (en) 2018-09-11
EP3022230B1 (en) 2019-11-06
US9732135B2 (en) 2017-08-15
JP2016529232A (ja) 2016-09-23
US20180057555A1 (en) 2018-03-01
IL243459A0 (en) 2016-03-31
EP3022230A1 (en) 2016-05-25
CA2918119C (en) 2022-11-29
US20180334488A1 (en) 2018-11-22

Similar Documents

Publication Publication Date Title
MX2016000721A (es) Direccionamiento de antagonistas de citocinas.
PH12016500141A1 (en) Methods of treating sporadic inclusion body myositis
PH12016500349B1 (en) Anti-prlr antibodies and uses thereof
MX2020013062A (es) Anticuerpos anti proteina relacionada con el receptor del factor de necrosis tumoral inducida por glucocorticoides (gitr) y sus metodos de uso.
MX2009008104A (es) Hepcidina, antagonistas de hepcidina y metodos de uso.
PH12018502538A1 (en) Antibodies to alpha-synuclein and uses thereof
UA107782C2 (ru) Антагонисты рецепторов fgf-r4
PH12015502565B1 (en) Anti-transferrin receptor antibodies and methods of use
MX2016000611A (es) Fusocinas que implican citocinas con una afinidad de union al receptor considerablemente menor.
AU2014284235B2 (en) Methods for treating nasal polyposis by administering an IL-4R antagonist
MX2019010846A (es) Polipeptidos de il-22 y proteinas de fusion de il-22 fc y metodos de uso.
PE20150891A1 (es) Anticuerpos anti-receptor de il-13 alfa 2 y conjugados de anticuerpo farmaco
WO2014145159A3 (en) Charge-engineered antibodies or compositions of penetration-enhanced targeting proteins and methods of use
MX2013009679A (es) Anticuerpos del receptor anti-interleucina-6 (anti-il-6) y sus metodos de uso.
WO2015069922A3 (en) Alk antibodies, conjugates, and chimeric antigen receptors, and their use
MX2020003503A (es) Proteinas de union al antigeno del receptor de oncostatina m.
PH12016500123A1 (en) Therapeutic fusion protein
EA201491107A1 (ru) Антитела к рецептору эпидермального фактора роста 3 (her3), направленные на домен ii her3
TR201903312T4 (tr) Benralizumab kullanarak astım alevlenme oranlarini azaltma yöntemleri.
MX2015000754A (es) Proteinas de btnl3, acidos nucleicos, y anticuerpos y los usos de los mismos.
MX2015005928A (es) Metodos para tratar el cancer de ovario con antagonistas de dll4.
PH12019501605A1 (en) Glucagon receptor binding proteins and methods of use thereof
WO2008150495A8 (en) vWF APTAMER FORMULATIONS AND METHODS FOR USE
PH12018500131A1 (en) Il22 immunoconjugates
MX2020011668A (es) Antagonistas duales de receptores de neurocinina-1 (nk-1)/neurocinina-3 (nk-3) para el tratamiento de enfermedades dependientes de hormonas sexuales.

Legal Events

Date Code Title Description
HC Change of company name or juridical status

Owner name: SULZER MANAGEMENT AG

FG Grant or registration